

Registered charity number: 1185148

Report of the Trustees and
Unaudited Financial Statements
for the year ended 31 March 2022

for British Lymphology Society CIO

British Lymphology Society CIO
Contents of the Financial Statements
for the year ended 31 March 2022

	Page
Information page	1
Report of the Trustees	2
Independent Examiner's Report	3
Statement of Financial Activities	4
Balance Sheet	5
Notes to the Financial Statements	6

**British Lymphology Society CIO
Information Page
for the year ended 31 March 2022**

Registered Charity Number

1185148

Trustees

Chairperson - Margaret Sneddon

Vice Chairperson - Katie Riches

Treasurer - Peter Hooper-Smith (appointed 11/05/22)

Treasurer - Dawn Heal (resigned 11/05/22)

Trustees -

Rebecca Elwell

Catriona O'Neill

Lorraine Brown

Amit Arora

Jane Board

Rachael Hutton

Debra Allcock (appointed 08/11/21)

Yolande Borthwick (appointed 08/11/21)

Jenny Furniss (appointed 08/11/21)

Helen Masey (appointed 08/11/21)

Lucie Casserley (resigned 09/02/22)

Jill Hewitt (resigned 08/11/21)

Co-opted Trustee

Cheryl White

BLS Scientific Committee chair

Dr Rhian Noble-Jones

Independent Examiner

J Bardolph FCCA

Accountably Ltd

1st Floor, Unit 12

Compass Point

Ensign Way

Hamble

Southampton

Hampshire

SO31 4RA

**British Lymphology Society CIO
Report of the Trustees
for the year ended 31 March 2022**

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity registered with the Charity Commission on 3 September 2019, under registration number 1185148 and is a charitable incorporated organisation - CIO.

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The trustees have assessed the risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to the major risks.

OBJECTIVES AND ACTIVITIES FOR THE PUBLIC BENEFIT

The object of the CIO is the preservation and protection of good health among people in the UK living with lymphoedema/chronic oedema in particular by:

- Advancing education and knowledge in the field of lymphology and related subjects
- Fostering interest in and co-ordinating a strategy for improving the management of chronic oedema, particularly lymphoedema
- Producing and maintaining a register of specialist centres in the UK and Ireland
- Improving the knowledge, expertise and skills of healthcare professional who treat patients

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities.

ACHIEVEMENTS AND PERFORMANCE

It has been another challenging year for the charity due to the ongoing impact of Covid-19 but I am pleased to say we remain financially stable. We have built on the foundation of last year's cost optimisation and continued our drive to control our expenditure whilst delivering another a successful and profitable Virtual Conference. Travel and meeting room expenses remained minimal as all our Committee Meetings were held virtually. We have realised that this is an effective way of meeting up and will continue this way in the future. We continue to tightly monitor our finances to ensure we have adequate reserves. We held our yearly Conference on-line for the second year in a row and this was very well received. As the Covid-19 related restrictions have been relinquished we are looking forward to holding our first face-to-face Conference in October 2022. We continue to have generous financial support from our sponsors and members.

FINANCIAL REVIEW AND RESERVES POLICY

The relevant income, expenditure, cash and results for the year are shown under Unrestricted Funds, During the year the charity received income of £108,160.

It is currently the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a minimum level equivalent to six months' expenditure. It will be proposed to the board of trustees on 7 September 2022 that the policy extended to a period of 12 months' expenditure. The amendment to the policy will ensure that reserves at this increased level will ensure that, in the event of a significant drop in funding, that the trustees will be able to continue the charity's activities while consideration is given to ways in which additional funds may be raised. The six months' expenditure level of reserves was achieved throughout the period under review.

INDEPENDENT EXAMINER


Jonathan Bardolph FCCA has been re-appointed as independent examiner for the ensuing year.

9/9/2022

Approved by order of the board of trustees on.....

and signed on its behalf by:

DocuSigned by:



6E5C807518094DE
Margaret Smeddoff - Chairperson

British Lymphology Society CIO
Independent Examiner's Report to the Trustees
for the year ended 31 March 2022

I report to the trustees on my examination of the accounts of the above charity for the year ended 31 March 2022.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").


I report in respect of my examination of the charity's accounts as carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in, any material respect:

1. the accounting records were not kept in accordance with section 130 the Charities Act; or
2. the accounts did not accord with the accounting records; or
3. the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a "true and fair" view which is not a matter considered as part of an independent examination

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

DocuSigned by:

.....649A96C835894EB...
J Bardolph FCCA
Independent Examiner

Accountably Ltd
1st Floor, Unit 12
Compass Point
Ensign Way
Hamble
Southampton
Hampshire
SO31 4RA
9/9/2022
.....

British Lymphology Society CIO
Statement of Financial Activities
for the year ended 31 March 2022

	Notes	Unrestricted fund £	Restricted fund £	2022 Total funds £	2021 Total funds £
INCOMING RESOURCES					
Incoming resources from generated funds					
Voluntary income	2	38,911	-	38,911	32,683
Charitable activities	3	69,029	-	69,029	111,894
Investment income	4	218	2	220	648
Total incoming resources		108,158	2	108,160	145,225
RESOURCES EXPENDED					
Charitable activities	5	89,330	-	89,330	77,652
Governance costs	6	5,045	-	5,045	4,915
Total resources expended		94,375	-	94,375	82,567
NET INCOMING RESOURCES and net income for the year		13,783	2	13,785	62,658
Net movement in funds		13,783	2	13,785	62,658
RECONCILIATION OF FUNDS					
Total funds brought forward	9	200,489	22,358	222,847	160,189
TOTAL FUNDS CARRIED FORWARD	9	214,272	22,360	236,632	222,847

The Statement of Financial Activities includes all gains and losses in the year and therefore a statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.


The notes form part of these financial statements.

British Lymphology Society CIO
Balance Sheet
as at 31 March 2022


		2022	2021
	Notes	Total funds	Total funds
		£	£
CURRENT ASSETS			
Debtors	7	75,154	1,348
Cash at bank		259,926	271,511
		<u>335,080</u>	<u>272,859</u>
CREDITORS			
Amounts falling due within one year	8	(98,448)	(50,012)
		<u></u>	<u></u>
NET CURRENT ASSETS		236,632	222,847
		<u></u>	<u></u>
NET ASSETS		236,632	222,847
		<u><u></u></u>	<u><u></u></u>
FUNDS	9		
Unrestricted funds:		214,272	200,489
Restricted funds		22,360	22,358
		<u></u>	<u></u>
TOTAL FUNDS		236,632	222,847
		<u><u></u></u>	<u><u></u></u>

9/9/2022

The financial statements were approved by the Board of Trustees on and were signed on its behalf by:

DocuSigned by:

 6E5C807518094DE.....

Chairperson - Margaret Sneddon

DocuSigned by:

 04CA2159779A406.....

Treasurer - Peter Hooper-Smith

The notes form part of these financial statements.

British Lymphology Society CIO
Notes to the Financial Statements
for the year ended 31 March 2022

1 ACCOUNTING POLICIES

(a) ***Basis of preparation of the accounts***

The accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to the accounts. The accounts have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) effective January 2019.

(b) ***Funds***

General funds represent the funds of the charity that are not subject to any restrictions regarding their use and are available for application for general purposes. Funds designated for a particular purpose by the charity are also unrestricted. Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

(c) ***Incoming resources***

Donations, legacies and other forms of voluntary income are recognised as incoming resources when receivable, except in so far as they are incapable of financial measurement.

Trading income is shown net of related expenses as this better reflects the contribution of these activities to the charity.

Income tax recoverable in relation to donations received under Gift Aid is recognised at the time of the donation.

(d) ***Resources expended***

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity. Governance costs are those associated with the governance arrangements of the charity.

(e) ***Taxation***

The charity is exempt from corporation tax on its charitable activities.

	Unrestricted funds £	Restricted funds £	Total funds 2022 £	Total funds 2021 £
2 VOLUNTARY INCOME				
Membership subscriptions	38,911	-	38,911	32,683
	<u>38,911</u>	<u>-</u>	<u>38,911</u>	<u>32,683</u>

British Lymphology Society CIO
Notes to the Financial Statements
for the year ended 31 March 2022

3 CHARITABLE ACTIVITIES	Unrestricted funds £	Restricted funds £	Total funds 2022 £	Total funds 2021 £
Conference	61,669	-	61,669	77,033
Advertising and other services	7,360	-	7,360	34,861
	<u>69,029</u>	<u>-</u>	<u>69,029</u>	<u>111,894</u>
4 INVESTMENT INCOME	Unrestricted funds £	Restricted funds £	Total funds 2022 £	Total funds 2021 £
Interest receivable	<u>218</u>	<u>2</u>	<u>220</u>	<u>648</u>
5 EXPENDITURE - Charitable activities	Unrestricted funds £	Restricted funds £	Total funds 2022 £	Total funds 2021 £
Professional fees	1,162	-	1,162	40
Office and administration costs	59,200	-	59,200	58,858
Website, computer and internet costs	1,318	-	1,318	875
Newsletter	2,965	-	2,965	4,489
Conference	947	-	947	2,814
Promotional items and surveys	3,470	-	3,470	2,027
Wages and expenses	20,268	-	20,268	20,269
2020 campaign	-	-	-	7,488
Written off previous years' supplier balances	-	-	-	(19,208)
	<u>89,330</u>	<u>-</u>	<u>89,330</u>	<u>77,652</u>

British Lymphology Society CIO
Notes to the Financial Statements
for the year ended 31 March 2022

6 EXPENDITURE - Governance costs

	Unrestricted funds £	Restricted funds £	Total funds 2022 £	Total funds 2021 £
Book-keeping	2,232	-	2,232	2,418
Independent examiner	1,800	-	1,800	1,572
Insurance	790	-	790	635
Committee meetings	223	-	223	110
Other meetings	-	-	-	180
	<hr/> 5,045	<hr/> -	<hr/> 5,045	<hr/> 4,915
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

7 DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Trade debtors	70,461	574
Other debtors	4,693	774
	<hr/> 75,154	<hr/> 1,348
	<hr/> <hr/>	<hr/> <hr/>

8 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Trade creditors	11,248	-
Deferred income	83,710	42,723
Accrued charges	3,490	7,289
	<hr/> 98,448	<hr/> 50,012
	<hr/> <hr/>	<hr/> <hr/>

9 MOVEMENT ON UNRESTRICTED AND RESTRICTED FUNDS

	Balance at 1 April 2021 £	Incoming resources £	Outgoing resources £	Transfers between funds £	Balance at 31 March 2022 £
Unrestricted					
General fund	200,489	108,158	(94,375)	-	214,272
Restricted fund:					
Scientific research	22,358	2	-	-	22,360
	<hr/> 222,847	<hr/> 108,160	<hr/> (94,375)	<hr/> -	<hr/> 236,632
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

British Lymphology Society CIO
Notes to the Financial Statements
for the year ended 31 March 2022

10 ANALYSIS OF NET ASSETS BETWEEN FUNDS	Tangible fixed assets £	Net current assets £	Total £
Unrestricted:			
General fund	-	214,272	214,272
Restricted:			
Scientific research	-	22,360	22,360
	<u>-</u>	<u>236,632</u>	<u>236,632</u>

11 OTHER BENEFITS RECEIVED BY THE CHARITY

We are grateful to our corporate members for their generosity and their support in the 2021 conference. In addition, thank you to all who sponsor us in formal and informal ways.

12 TRUSTEES REMUNERATION AND EXPENSES

The following trustees received reimbursement of expenses during the year:

	£
M Sneddon	96
R Noble-Jones	60

No trustee nor anyone connected with them received any remuneration during the period in respect of their services as trustees.